If you have type 2 diabetes, your doctor might suggest Invokana (canagliflozin) as a treatment option for you. Invokana is a prescription medication that’s used in adults with type 2 diabetes to: ...

The US Food and Drug Administration (FDA) has strengthened its warning for canagliflozin (Invokana, Invokamet, Johnson & Johnson/Janssen) related to the increased risk for bone fractures. The "Adverse ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a once-daily, fixed-dose combination therapy of the SGLT2 inhibitor canagliflozin and ...

The US Food and Drug Administration (FDA) has approved a fixed-dose combination product combining the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin with metformin hydrochloride for ...

Authors report theirs is the first real-world study comparing the 2 SGLT2 inhibitors. A recently published study that compared patients with type 2 diabetes (T2D) taking the highest dose of ...

Canagliflozin Provided Substantial and Sustained Glycemic Improvements as Monotherapy and in Add-On Combinations in Adults with Type 2 Diabetes in Five Phase 3 Studies Canagliflozin Provides Greater ...

In Phase 3 studies, INVOKANA™ improved blood glucose control and was associated with reductions in body weight and systolic blood pressure Janssen will partner with other Johnson & Johnson companies ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. CHICAGO — Long-term canagliflozin use was associated ...

Regulators based their probe on results from an ongoing clinical trial, called Canagliflozin Cardiovascular Assessment Study (CANVAS), which is slated to finish in 2017. The study is tracking about ...

Poster presentations at the American Diabetes Association Scientific Sessions compared canagliflozin, an SGLT2 inhibitor, to sitagliptin, a popular DPP-4 inhibitor, using claims data. At the 2016 ...